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CD5
ϩ B (or B-1) cells are a unique subset of B cells that are distinguishable from the conventional B or B-2 cells in terms of their phenotype, anatomical localization, and self-renewal properties (1) . For example, B-1 cells are found in the pleural and peritoneal cavities and express a high level of IgM and low levels of IgD and the pan B-cell marker B220 on their cell surfaces. In addition, they express an intermediate level of the T-cell marker CD5. On the other hand, B-2 cells predominate in the spleen and lymph nodes and express intermediate levels of IgM and IgD and a high level of B220, and they lack CD5 expression on their cell surfaces. The origin of B-1 cells is controversial, and it remains to be determined whether they are derived from a separate B cell lineage (2) or represent a state of differentiation or activation of normal B lymphocytes (3) . However, B-1 cells are known to secrete natural polyreactive antibodies found in the serum and often have specificities directed toward self-antigens such as phosphatidylcholine (4), single-stranded DNA (5), ribonucleoprotein (6) , and the cell surface Thy-1 antigen (7) . In addition, B-1 cells frequently give rise to B-cell chronic lymphocytic leukemia (B-CLL).
1 B-1 cells also differ from B-2 cells in their functional responses to external stimuli. For example, engagement of the B cell antigen receptor (BCR) leads to the proliferation of B-2 cells, but such entry into the cell cycle is blocked in B-1 cells (8, 9) . This difference in physiological response suggests that B-1 cells may have signaling properties that are different from B-2 cells.
The BCRs on both B-1 and B-2 cells are composed similarly of the Ig heavy and light chains in complex with the signaling subunits Ig␣ and Ig␤ (10) . BCR signaling is known to activate numerous signal transduction pathways, and the induction of a particular pathway may depend on the state of differentiation of the B lymphocyte and may lead to distinct cellular outcomes (11) . Signaling differences in response to BCR engagement have been documented between immature and mature B cells, and these differences may lead to cell death in the former but activation in the latter (12, 13) . Naïve B cells that have yet to encounter antigens and tolerant B cells that are chronically exposed to self-antigens also differ in their BCR signaling events, in particular the activation of the mitogen-activated protein kinases (MAPKs) and the transcription factors NF-B and NF-AT (14) .
The MAPKs are serine/threonine protein kinases, and they couple receptor signaling to cellular responses such as proliferation, differentiation, and cell death (15) . The three major classes of MAPKs are the extracellular signal-regulated kinase (ERK), the c-Jun NH 2 -terminal kinase (JNK), and the p38 MAPK (16) . ERK has been implicated in cell growth and proliferation (17) , whereas JNK and p38 MAPK appear to be involved in stress response and apoptosis (18, 19) . Cross-linking of the BCR activates all three classes of MAPKs in naïve B cells, but only ERK is activated in tolerant B cells (14) , whereas the activation of p38 MAPK is not known. The transcription factor NF-B regulates genes involved in survival and prolif-eration (20) , whereas NF-AT seems to regulate genes involved in cellular homeostasis and differentiation (21) . BCR signaling induces the activation of both NF-B and NF-AT in naïve B cells, whereas the activation of NF-AT is constitutive but that of NF-B is blocked in tolerant B cells (14) .
Since differences in BCR signaling have been documented between immature and mature B cells and between naïve and tolerant B cells, it is assumed that B-1 and B-2 cells may also differ in their induction of the various signaling pathways. Indeed, it is known that the activation of the transcription factor STAT-3 is constitutive in B-1 cells but only induced in B-2 cells (22) . Therefore, in this report, we systematically examine whether the various common signaling pathways that are induced by BCR engagement in B-2 cells, namely those of phospholipase C (PLC)-␥2, MAPKs, Akt, NF-B, and NF-AT, are also differentially activated in B-1 cells. The study of the signaling pathways activated by BCR engagement on B-1 cells may shed light to the origins of this subset of B lymphocytes.
EXPERIMENTAL PROCEDURES
Mice-The V H 12f (23) and wild-type BALB/c mice were maintained in our animal facility and used to isolate B-1 and B-2 cells, respectively. All mice were used between 2 and 5 months of age and in accordance with institutional guidelines.
Flow Cytometry-Peritoneal cavity and splenic B cells were stained with fluorochrome-conjugated antibodies (Abs) for 15 min on ice. After washing in phosphate-buffered saline containing 3% fetal calf serum and 0.01% NaN 3 , the cells were analyzed on a FACScan (Becton Dickinson) using Cell Quest Software. The following Abs used in the FACS analyses were obtained from PharMingen (San Diego, CA): antiIgM (R6 -60.2), anti-IgD, anti-B220 (RA3-6B2), anti-CD5, anti-CD23, anti-CD25, anti-CD69, and anti-CD86 (B7.2). The anti-V H 12 (5C5) Ab was obtained previously from Dr. G. Haughton (University of North Carolina, Chapel Hill, NC).
Purification and Treatment of Cells-To obtain a pure population of B-1 cells, peritoneal cavity washout of V H 12f mice was seeded onto a tissue culture dish for 2-3 h to remove adherent macrophages. B-2 cells were isolated from splenocytes of wild-type mice by MACS using negative selection with anti-CD43 microbeads (Miltenyl Biotech). The purity of B-1 and B-2 cells obtained is Ͼ85% as assessed by FACS analysis using anti-IgM and anti-B220 Abs. Purified cells were cultured in complete RPMI 1640 medium with serum except in the JNK and p38 MAPK experiments, where the serum supplement was omitted. For the NF-B experiment, the cells were cultured in OPTI-MEM I reduced serum medium (Invitrogen). For the IB␣ assays, cells were treated with 50 M cycloheximide (Sigma) before and during the various stimulations. B cells (1-5 ϫ 10 6 ) were left untreated or stimulated with 10 -50 g/ml goat anti-mouse IgM F(abЈ) 2 fragment (Jackson Immunoresearch), a combination of 0.1 g/ml PMA and 1 g/ml ionomycin (Sigma), or 1 g/ml lipopolysaccharide (LPS) (Sigma) for various times at 37°C prior to the conduct of the various assays. Treatment of cells with the MEK1 inhibitor U0126 (Cell Signaling Technology, Beverly, MA), PD98059, or the inactive analog SB202474 (Calbiochem) was performed at concentrations ranging from 1 to 100 M.
Proliferation Assay-Purified B cells (5 ϫ 10 5 ) that were either nontreated or stimulated with various amounts of anti-IgM F(abЈ) 2 antibody or LPS were cultured for 42 h in a 96-well flat-bottomed plate at 37°C in the presence of 7% CO 2 . Cells were subsequently pulsed with 1 Ci of [ 3 H]thymidine (Amersham Biosciences) and harvested 6 h later with a Skatronas cell harvester (Skatronas Instruments Inc.). The incorporation of radioactivity was measured by a Wallac LKB 1219 Rackbeta liquid scintillation counter (PerkinElmer Life Sciences).
Preparation of Nuclear Extracts-Cells were lysed on ice in hypotonic buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 0.2 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 2.5 g/ml aprotinin, and 2.5 g/ml leupeptin) for 5 min. After the addition of 0.2% Nonidet P-40, the cell lysate was passed through a 26-gauge needle to ensure the complete lysis of cells and centrifuged at 13,000 rpm for 3 min at 4°C. The nuclear pellet was washed twice in the hypotonic buffer; resuspended in a high salt buffer that contains 20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 0.02% Nonidet P-40, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 2.5 g/ml aprotinin, and 2.5 g/ml leupeptin; and incubated on a Spiramix roller mixer for 30 min at 4°C. The nuclear fraction was subsequently cleared of insoluble material by centrifugation at 13,000 rpm for 5 min at 4°C before desalting and concentrating with a microcon-3 column (Millipore Corp.). The nuclear extracts were stored at Ϫ80°C prior to use, and the protein content was measured using a Bio-Rad DC protein assay (Bio-Rad).
Electrophoretic Mobility Shift Assays-For the NF-B gel shift assay, 10 g of the nuclear extracts was incubated with a [␣-
32 P]dATP-labeled probe that contains the sequence 5Ј-AGTTGAGGGGACTTTCCCAGG-C-3Ј and 5 g of poly(dI⅐dC) in buffer A (12 mM Hepes, pH 7.9, 4 mM Tris-HCl, pH 7.9, 60 mM KCl, 30 mM NaCl, 5 mM MgCl 2 , 5 mM dithiothreitol, and 12.5% glycerol). For the NF-AT gel shift assay, 10 g of nuclear extracts was incubated with 1 g of poly(dI⅐dC) and a labeled probe that contains the sequence 5Ј-CGCCCAAAGAAGAAAATTTGTT-TCATA-3Ј in gel shift buffer B (21.5 mM Hepes, pH 7.9, 84 mM NaCl, 1 mM EDTA, 1.2 mM dithiothreitol, 0.1% glycerol, and 300 g/ml bovine serum albumin). The reaction mixture was incubated for 20 min at room temperature prior to electrophoresis in a 5% nondenaturing PAGE.
Immunoprecipitations and Western Blot Analyses-Cells (10 6 to 10 7 ) were lysed on ice for 15 min in a buffer that contains 1% (v/v) Nonidet P-40, 10 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM EDTA, 0.2 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, and 10 g/ml aprotinin, and the debris was removed by centrifugation at 13,000 rpm for 12 min at 4°C. For immunoprecipitations, cell lysates were sequentially incubated with 2-2.5 g of appropriate antibodies and protein A/G PLUSagarose beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The immunoprecipitates or lysates were electrophoresed in a 7-10% SDS-PAGE, electroblotted onto polyvinylidene difluoride membrane, and probed with Abs that recognize specific proteins. Protein bands were visualized using horseradish peroxidase-coupled Abs and the enhanced chemiluminescence detection system (Amersham Biosciences). The following Abs were used: anti-phosphotyrosine (PY20); anti-PY20-agarose and anti-Bcl-x L (Transduction Laboratories, San Diego, CA); antiBruton's tyrosine kinase (anti-Btk) (PharMingen); anti-phospho-ERK, anti-ERK2, anti-JNK1, anti-TFIID, anti-IB␣, anti-PLC-␥2, and antitubulin (Santa Cruz Biotechnology); anti-phospho-JNK, anti-phosphop38, anti-p38 MAPK, anti-Akt, and anti-phospho-Akt S473 (Cell Signaling Technology, Beverly, MA); and anti-phospho-Akt T308 (Upstate Biotechnology, Inc., Lake Placid, NY).
In Vitro Kinase Assay for ERK-ERK was immunoprecipitated from lysates of nontreated or anti-IgM-stimulated cells using anti-ERK2 Ab and protein A/G PLUS-agarose beads. After washing in 1% Nonidet P-40 buffer, the immunoprecipitate was resuspended in a mixture that contains the myelin basic protein substrate as detailed in the MAPK assay kit (Upstate Biotechnology).
D-myo-Inositol 1,4,5-Trisphosphate Assay for PLC␥ Activity-5 ϫ 10 6 purified B cells that were either nontreated or stimulated with anti-IgM were lysed, and the generation of D-myo-inositol 1,4,5-trisphosphate (IP 3 ) was measured as previously described (24, 25) , using the BIO-TRAK TRK 1000 kit (Amersham Biosciences). Briefly, unlabeled IP 3 generated by the cells was used to compete with a fixed, known amount of [ 3 H]IP 3 for binding to a limited number of IP 3 receptors present in the bovine adrenal glands homogenate provided by the kit. The bound IP 3 is separated from the free IP 3 by centrifugation, which pellets the IP 3 -receptor complexes. The free IP 3 in the supernatant was discarded by decantation. Measurement of the amount of radioactivity bound to the receptor enables one to estimate the amount of unlabelled IP 3 in the sample as determined by interpolation from a standard curve. We have previously generated a strain of immunoglobulin knock-in mice, designated V H 12f (23) , that carry a V H 12 Ig heavy chain transgene. The V H 12 heavy chain is derived from an antibody that recognizes phosphatidylcholine (27) , an anti-genic specificity that is enriched in B-1 cells. Not surprisingly, as shown in Fig. 1A , V H 12f mice develop predominantly B-1 cells that are IgM high B220 low CD5 ϩ IgD Ϫ (23). In addition, as shown in Fig. 1B , close to 90% of the B cells in the peritoneal cavity of V H 12f mice express the knock-in V H 12 heavy chain as identified by FACS staining with the idiotypic anti-V H 12 Ab. As such, these mice would provide an ideal source of B-1 cells for biochemical analyses. To ensure the relevance of using the transgenic V H 12-expressing B-1 cells, we show that V H 12-expressing B cells are naturally occurring and formed a sizable fraction (close to 2%) of the normal B-1 cell repertoire in the peritoneal cavity of wild-type mice.
RESULTS

V H 12-expressing B-1 Cells Are Found in Normal Mice
Next, we showed that V H 12-expressing B-1 cells can be isolated with great purity from the peritoneal cavity of V H 12f mice (Fig. 1C ) using a procedure that does not lead to the stimulation of the BCR. Similarly, conventional B-2 cells can also be purified from the spleens of wild-type mice for comparative study. Thus, the use of transgenic V H 12-expressing B-1 cells from the peritoneal cavity of V H 12f mice (23) would greatly facilitate the study of the biochemical properties of B-1 cells.
Transgenic V H 12-expressing B-1 Cells Do Not Proliferate in Response to BCR Engagement but Exhibit Extended Survival in
Vitro-To further ensure that the transgenic V H 12-expressing B-1 cells behave like normal B-1 cells found in wild-type mice, we examined their response to BCR stimulation. In all experiments described in this paper, BCR signaling is induced using anti-IgM F(abЈ) 2 antibodies. It is known that B-1 cells, unlike B-2 cells, do not proliferate when their BCRs are cross-linked (28). Indeed, transgenic V H 12-expressing B-1 cells did not respond to anti-IgM stimulation regardless of the dosage given ( Fig. 2A) . This was in contrast to the dose-dependent proliferation of B-2 cells. However, as control, we showed that V H 12-expressing B-1 cells were not completely refractory to stimulation, since they did proliferate in response to LPS treatment, albeit to a much lesser extent compared with B-2 cells (Fig. 2B) .
Another property of B-1 cells is their extended survival in culture compared with B-2 cells (29) . In contrast to B-2 cells that undergo apoptosis rapidly within a day in culture, V H 12-expressing B-1 cells can survive for extended period of time in vitro without dying, as shown in Fig. 2C . Taken together, the data suggest that the transgenic V H 12-expressing B-1 cells behave like normal B-1 cells and further support the notion that they would serve as a suitable model system to study the properties of this unique subset of B cells. Henceforth, V H 12-expressing B-1 cells will be designated simply as B-1 cells.
Lack of BCR-induced NF-B Activation in B-1 Cells-Given the physiological differences seen in B-1 and B-2 cells, in particular in their different proliferative response to BCR crosslinking, we proceeded to examine if BCR stimulation would induce different signaling events in these two B cell subsets.
BCR signaling is known to activate the transcription factor NF-B that regulates genes involved in cell proliferation and survival (30) . The predominant form of NF-B in B cells is the p50-c-Rel heterodimer (31) , and in particular, c-Rel is shown to be essential for B cell proliferation after BCR engagement (31) (32) (33) .
As expected, treatment of B-2 cells with anti-IgM or a combination of PMA and ionomycin led to the activation of NF-B in these cells, as evidenced by the increased binding of nuclear NF-B proteins to an oligoprobe that contained the NF-B consensus binding site (Fig. 3A, right) . In contrast, there was no significant induction of NF-B above the background level in BCR-stimulated B-1 cells, and as control, the treatment of B-1 cells with PMA and ionomycin did result in the activation of this transcription factor (Fig. 3A, left) .
To confirm that NF-B was indeed not activated in BCR- with anti-IgM antibodies did not lead to the expression of Bcl-x L , consistent with a lack of NF-B activation in these cells. As control, B-1 cells did express Bcl-x L after LPS treatment. Taken together, the data indicate that NF-B is not activated in B-1 cells after BCR stimulation.
To determine the reason for the lack of NF-B activation in B-1 cells, we next examined the molecular events leading to its activation. In nonstimulated cells, NF-B/Rel factors are sequestered in the cytoplasm by the inhibitory (I)-B family of proteins (36) . Upon specific stimulation, the IB kinases are activated, and this leads to the serine/threonine phosphorylation and subsequent degradation of IB proteins and the release of NF-B/Rel proteins for translocation into the nucleus to effect gene transcription (37, 38) . As shown in Fig. 3C , treatment of B-2 cells with anti-IgM antibodies or a combination of PMA and ionomycin led to the degradation of the IB proteins as indicated by the loss of IB␣ subunit in Western blot analyses of whole cell lysates. Concomitantly, there was an increase in c-Rel translocation into the nucleus of anti-IgM-or PMA/ionomycin-stimulated B-2 cells (Fig. 3D) . In contrast, IB␣ proteins were not degraded in IgM-stimulated B-1 cells (Fig. 3C) , and there was a lack of c-Rel translocation into the nucleus of these cells (Fig. 3D) . Again, as control, IB␣ could be degraded, and nuclear translocation of c-Rel was effected in PMA/ionomycin treated B-1 cells. Thus, in B-1 cells, IB proteins specifically do not degrade in response to BCR signaling, and this results in a lack of NF-B activation in these cells. (39 -41) . In B cells, the Btk-PLC-␥2 pathway has been shown to be essential for NF-B activation in B cells (42) . Hence, it is possible that the expression or activation of these signaling molecules may be altered in B-1 compared with B-2 cells. Thus, we first examined the activation of Btk in nontreated and anti-IgM-stimulated B-1 and B-2 cells. Western blot analysis of tyrosinephosphorylated Btk indicated that Btk was activated with the same kinetics in both anti-IgM-stimulated B-1 and B-2 cells (Fig. 4A) . Next, we examined the activation of the downstream PLC-␥2 in nontreated and anti-IgM-stimulated B-1 and B-2 cells. As shown in Fig. 4B , PLC-␥2 was expressed equivalently in both B-1 and B-2 cells and could be activated by anti-IgM treatment. However, in B-1 cells, the PLC-␥2 activation appeared to tail off faster at the 30 s time point. Since the intact phosphorylation of PLC-␥2 in B-1 cells seems inconsistent with the lack of NF-B activation, we directly examined the enzymatic activity of PLC-␥2. PLC-␥2 catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P 2 ) into diacylglycerol and IP 3 . Hence, its activity can be assayed by measuring the production of IP 3 . As shown in Fig. 4C , the generation of IP 3 was observed to be reduced in anti-IgM-stimulated B-1 cells as compared with that of B-2 cells. Hence, the reduced activity of PLC-␥2 in B-1 cells may impact upon NF-B activation after BCR stimulation.
Intact Btk but Reduced PLC-␥2 and Lack of Protein Kinase B/Akt Activation in IgM-stimulated B-1 Cells-Two signaling pathways have been linked to NF-B activation
Another signaling pathway that is activated by the crosslinking of the BCR on B-2 cells is that of the serine/threonine kinase, Akt, or protein kinase B (43, 44) . Akt is an important signaling molecule that has also been implicated in the activation of NF-B (39, (45) (46) (47) and in cell survival (48, 49) in many different biological systems. We therefore also examined the activation status of Akt in B-1 cells.
The activity of Akt is dependent on phosphorylation, and Akt can be phosphorylated on two potential sites: Thr 308 and Ser 473 . Western blot analyses using specific antibodies that recognized either of the phosphorylated residues of Akt indicated that both sites were phosphorylated in BCR-stimulated B-2 cells (Fig. 4D) (14) .
To determine the pattern of MAPK activation in B-1 cells, we stimulated these cells with anti-IgM antibodies for various times, and the activation of the different classes of MAPKs was examined using phosphorylation state-specific antibodies. Anti-IgM-treated B-2 cells were used as controls, since all classes of MAPKs could be activated in these cells following stimulation.
As shown in Fig. 5A , Western blot analysis using anti-phospho-ERK antibody indicated that ex vivo B-1 cells had a basal level of constitutive ERK activation compared with B-2 cells. This basal level of ERK activation in B-1 cells could be further up-regulated as indicated by the increased amount of phosphorylated ERK that was detected after anti-IgM stimulation (Fig.  5B ). An in vitro kinase assay using myelin basic protein as a substrate indicates that this basal level of phospho-ERK in B-1 cells was indeed active (Fig. 5C ). In contrast, although ERK was activated in B-2 cells within 3 min and sustained for at least 30 min after anti-IgM stimulation, there was clearly a lack of basal ERK activity in these cells as shown by a lack of anti-phospho-ERK antibody staining or ERK activity in phosphorylating the myelin basic protein substrate (Fig. 5, A and  C) . Furthermore, BCR stimulation seemed to induce a greater level of phosphorylation and hence activation of ERK in B-1 cells compared with B-2 cells (Fig. 5B) .
Examination of JNK activation also revealed a difference in the induction of this MAPK in B-1 and B-2 cells. Whereas JNK activation occurred within 3 min and was sustained for at least 10 min after anti-IgM treatment of B-2 cells, the kinetics of JNK activation was very much delayed to the 10-min time point in B-1 cells (Fig. 5D) .
Finally, analysis of p38 MAPK activation using anti-phospho-p38 MAPK antibody indicated that there was hardly any induction of this kinase above the basal level in anti-IgMstimulated B-1 cells (Fig. 5E ) compared with similarly treated B-2 cells, where the activation of p38 MAPK was noticeable within 3 min and maintained for at least 10 min after BCR stimulation.
Taken together, the above data indicate that B-1 cells have constitutive basal ERK activity and delayed JNK and lack p38 MAPK activation compared with B-2 cells, where all of these MAPKs are inducibly activated after BCR engagement.
Extended (Fig. 5A) . Constitutive ERK activation has been implicated in the maintenance of cell survival in many biological systems (51) . One of the distinguishing features of B-1 cells as shown in Fig. 2C is their extended survival in culture compared with B-2 cells, which undergo cell death rapidly ex vivo in the absence of stimulation (52) . Interestingly, the phosphorylated and hence activated form of ERK could be detected not only in ex vivo B-1 cells but also in B-1 cells that were in culture for up to 10 days without any BCR stimulation (Fig. 6A) . We thus determined whether the constitutive activation of ERK plays a role in B-1 cell survival in culture by incubating B-1 cells in the continuous presence of the inhibitor PD98059 or U0126 that acts on the upstream kinase MEK1, which phosphorylates ERK. The addition of the compound PD98059 but not its inactive analog SB202474 at a concentration of 50 M was sufficient to completely abrogate the phosphorylation of ERK and yet remained nontoxic to the cells (Fig. 6B, upper panel) . Similarly, the addition of 1 M U0126 was sufficient to inhibit ERK activation (Fig. 6B, lower panel) . However, the number of viable B-1 cells remained unchanged after 24 h (Fig. 6C ) or 48 h (data not shown) of culture in the presence of either of the inhibitors. Thus, the constitutive activation of ERK appears not to be responsible for the extended survival of B-1 cells in culture.
Constitutive Activation of NF-AT in B-1 Cells-The lack of NF-B activation and the differential induction of MAPKs in B-1 cells are reminiscent of that of tolerant B cells that are chronically exposed to self-antigens (14) . This raises the interesting possibility that B-1 cells may have signaling properties similar to those found in tolerant B cells. Another signaling pathway that is differentially induced in tolerant and naïve B-2 cells is that of NF-AT, which is constitutively active in the former but inducible in the latter (14) . In addition, it was reported that human B-CLL cells, which are CD5 ϩ , have constitutive NF-AT activation (53) . Since B-1 cells frequently give rise to B-CLL (54, 55) and have BCR specificities directed toward self-antigens, we examined the pattern of NF-AT activation in B-1 cells. Indeed, as shown in Fig. 7, ex (8, 9, 11, 14) . To determine whether other parameters of activation are also altered in B-1 cells, we examined the upregulation of activation markers on these cells after BCR stimulation. As shown in Fig. 8 The lack of NF-B activity in the nucleus of BCR-stimulated B-1 cells had previously been documented (56) . However, in this report, we explore further the reason for the lack of NF-B induction in BCR-stimulated B-1 cells and show that this is due to a lack of induced degradation of the IB proteins in the cytoplasm.
Two major signaling pathways are known to lead to NF-B activation, namely that of the PLC-␥2 and the Akt pathways. Whereas the activation of the nonreceptor tyrosine kinase Btk is normal in both BCR-stimulated B-1 and B-2 cells, the activity of PLC-␥2 as assessed by PI(4,5)P 2 hydrolysis was observed to be reduced in B-1 cells in response to the cross-linking of the BCR. It is not clear at present if the lower amount of IP 3 generated in B-1 cells is due to a reduction in PLC-␥2 activation, its localization, or a shortage of its substrate PI(4,5)P 2 . The reduction in PLC-␥2 activity and the impaired Akt activation in B-1 cells may explain the lack of NF-B induction in these cells. In turn, the lack of NF-B activity in BCR-stimulated B-1 cells may be the reason why these cells do not proliferate upon BCR stimulation, since NF-B is known to induce the expression of cyclin D1 and Bcl-x L , both of which are required for cells to enter the cell cycle (57) (58) (59) .
Another interesting feature of B-1 cells is their ability to survive for extended periods of time in culture in contrast to normal primary B cells, which undergo rapid cell death ex vivo in the absence of stimuli. The extended survival of B-1 cells is not due to NF-B or Akt signaling, since these two pathways, which have been implicated in cellular survival, are neither constitutively activated nor induced by BCR engagement in these cells.
The MAPKs regulate cell growth, proliferation, differentiation, and cell death in various biological systems (15) (16) (17) (18) (19) , and it is currently not known what aspects of B-1 cell physiology are regulated by these kinases. Our data indicate that the enhanced survival of ex vivo B-1 cells is also not due to the constitutive activation of ERK, since inhibiting the activation of this kinase did not lead to more pronounced cell death. Since both JNK and p38 MAPK have been implicated in apoptosis (18, 19) , future experiments involving the enforced expression of these kinases are required to examine whether the failure to induce or sustain p38 MAPK and JNK activation in B-1 cell may explain their extended survival in vitro (52) .
One interesting finding in this report is the constitutive activation of the transcription factor NF-AT in B-1 cells. NFAT activation is regulated by Ca 2ϩ flux, which in turn can be regulated by PLC-␥2 activation through its hydrolysis of PI(4,5)P 2 into IP 3 and diacylglycerol. However, we are at present unable to correlate the constitute activation of NFAT in B-1 cells with the inducible manner of PLC-␥2 activation. Perhaps some intermediate product downstream of PLC-␥2 is altered in B-1 cells that leads to this phenomenon.
It was reported previously that human B-CLL cells, which were often CD5 ϩ , had constitutive activation of NF-AT (53). Recently, the enhancer region of the CD5 gene was found to contain multiple NF-AT binding sites (60) . Taken together, the data temptingly suggest that one of the characteristic features of the B-1 cell phenotype, namely the cell surface expression of CD5, may be due to the constitutive activation of this transcription factor. Indeed, consistent with this view, treatment of V H 12 transgenic mice that develop predominantly B-1 cells with cyclosporin A, an immunosuppressive drug that interferes with calcium signaling and hence NF-AT activation, prevented the generation of CD5 ϩ B cells (61) . The origins of B-1 cells have been controversial and debated for years (2, 3) . The pattern of MAPK, NF-AT, and NF-B signaling in B-1 cells described in this study closely resembles that of tolerant B cells that are chronically exposed to selfantigens (Table I) . B-1 cells also behave like tolerant B cells in that they do not proliferate upon BCR engagement (8, 9) . In addition, we show here that BCR-stimulated B-1 cells are not fully activated in terms of the expression of specific activation markers. These findings and the fact that B-1 cells often have autoreactive specificities temptingly suggest that B-1 cells may be a special class of anergic or tolerant B cells. They differ from the classical anergic B cells only in that B-1 cells persist in vivo and can survive for extended periods of time ex vivo.
In support of the argument that B-1 cells may be a special class of anergic B cells, we noted that B-1 cells are part of a normal B cell repertoire and often have specificities directed toward self-antigens such as DNA (5), ribonucleoprotein (6), and Thy-1 (7). The acquisition of CD5 expression on B-1 cells may be a consequence of the continuous recognition of selfantigen by their BCR, which constitutively activates the transcription factor NF-AT that may regulate CD5 gene expression (60) . Consistent with this observation, anti-Thy-1 B cells are CD5 ϩ only in the presence of Thy-1 (7). In the absence of Thy-1, anti-Thy-1 B cells resemble normal B-2 cells. Furthermore, transgenic B cells chronically exposed to the specific soluble antigen hen egg lysozyme do express low levels of cell surface CD5 and become unresponsive to BCR stimulation. However, upon the removal of CD5, these cells become hyperresponsive (62) . The expression of CD5, an inhibitory molecule that dampens BCR signaling (63) , may allow for the persistence of B-1 cells with polyreactive specificities and, at the same time, prevent a full-blown autoimmunity.
Finally (64) and BLNK (65) , which are the signaling molecules directly in the BCR signal transduction pathway. Mutations in other molecules or co-receptors such as CD19, PLC-␥2, Vav, and the p85 subunit of PI-3K that have a positive effect on BCR signaling or CD22, SHP-1, and Lyn, which exert a negative effect on BCR signal, resulted in mice with reduced or increased B-1 cells, respectively.
